Literature DB >> 23250007

Identification and characterization of antigens as vaccine candidates against Klebsiella pneumoniae.

Urban Lundberg1, Beatrice M Senn, Wolfgang Schüler, Andreas Meinke, Markus Hanner.   

Abstract

Nosocomial infections, also called "hospital acquired infections," occur worldwide and affect both developed and resource-poor countries, thus having a major impact on their health care systems. Klebsiella pneumoniae, which is an opportunistic Gram-negative pathogen, is responsible for causing pneumonia, urinary tract infections and septicemia in immune compromised hosts such as neonates. Unfortunately, there is no vaccine or mAb available for prophylactic or therapeutic use against K. pneumoniae infections. For this reason, we sought for a protein-based subunit vaccine capable of combating K. pneumoniae infections, by applying our ANTIGENome technology for the identification of potential vaccine candidates, focusing on conserved protein antigens present in strains with different serotypes. We identified numerous novel immunogenic proteins using genomic surface display libraries and human serum antibodies from donors exposed to or infected by K. pneumoniae. Vaccine candidate antigens were finally selected based on animal protection in a murine lethal-sepsis model. The protective and highly conserved antigens identified in this study are promising candidates for the development of a protein-based vaccine to prevent infection by K. pneumoniae.

Entities:  

Keywords:  ANTIGENome; Klebsiella pneumoniae; Nosocomial infections; active immunization; protection; vaccine candidates

Mesh:

Substances:

Year:  2012        PMID: 23250007      PMCID: PMC3891705          DOI: 10.4161/hv.23225

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  42 in total

1.  Epidemiology and prognostic determinants of bacteraemic biliary tract infection.

Authors:  M Ortega; F Marco; A Soriano; M Almela; J A Martínez; J López; C Pitart; J Mensa
Journal:  J Antimicrob Chemother       Date:  2012-03-09       Impact factor: 5.790

2.  Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae.

Authors:  L Goetsch; A Gonzalez; H Plotnicky-Gilquin; J F Haeuw; J P Aubry; A Beck; J Y Bonnefoy; N Corvaïa
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Identification of in vivo expressed vaccine candidate antigens from Staphylococcus aureus.

Authors:  Hildegard Etz; Duc Bui Minh; Tamás Henics; Agnieszka Dryla; Birgit Winkler; Christine Triska; Aoife P Boyd; Johannes Söllner; Walter Schmidt; Uwe von Ahsen; Michael Buschle; Steven R Gill; James Kolonay; Hanif Khalak; Claire M Fraser; Alexander von Gabain; Eszter Nagy; Andreas Meinke
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

4.  A gene, uge, is essential for Klebsiella pneumoniae virulence.

Authors:  Miguel Regué; Beatriz Hita; Nuria Piqué; Luis Izquierdo; Susana Merino; Sandra Fresno; Vicente Javier Benedí; Juan M Tomás
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

5.  Application of a novel multi-screening signature-tagged mutagenesis assay for identification of Klebsiella pneumoniae genes essential in colonization and infection.

Authors:  Carsten Struve; Christiane Forestier; Karen A Krogfelt
Journal:  Microbiology (Reading)       Date:  2003-01       Impact factor: 2.777

6.  Small-fragment genomic libraries for the display of putative epitopes from clinically significant pathogens.

Authors:  T Henics; B Winkler; U Pfeifer; S R Gill; M Buschle; A von Gabain; A L Meinke
Journal:  Biotechniques       Date:  2003-07       Impact factor: 1.993

7.  Passive immunization of mice against Klebsiella aerogenes.

Authors:  E A Roe; R J Jones; R E Dyster
Journal:  Br J Exp Pathol       Date:  1986-02

8.  Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.

Authors:  Hilmar Wisplinghoff; Tammy Bischoff; Sandra M Tallent; Harald Seifert; Richard P Wenzel; Michael B Edmond
Journal:  Clin Infect Dis       Date:  2004-07-15       Impact factor: 9.079

9.  Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

10.  Immunological properties of purified Klebsiella pneumoniae heat-stable enterotoxin.

Authors:  F A Klipstein; R F Engert; R A Houghten
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

View more
  17 in total

Review 1.  The role of vaccines in preventing bacterial antimicrobial resistance.

Authors:  Kathrin U Jansen; Charles Knirsch; Annaliesa S Anderson
Journal:  Nat Med       Date:  2018-01-09       Impact factor: 53.440

2.  Progress towards the development of Klebsiella vaccines.

Authors:  Myeongjin Choi; Sharon M Tennant; Raphael Simon; Alan S Cross
Journal:  Expert Rev Vaccines       Date:  2019-06-28       Impact factor: 5.217

3.  Identification of Outer Membrane and Exoproteins of Carbapenem-Resistant Multilocus Sequence Type 258 Klebsiella pneumoniae.

Authors:  Amanda J Brinkworth; Carl H Hammer; L Renee Olano; Scott D Kobayashi; Liang Chen; Barry N Kreiswirth; Frank R DeLeo
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

4.  Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity.

Authors:  Won-Hee Lee; Hyun-Il Choi; Sung-Wook Hong; Kwang-Sun Kim; Yong Song Gho; Seong Gyu Jeon
Journal:  Exp Mol Med       Date:  2015-09-11       Impact factor: 8.718

5.  Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.

Authors:  J N Dinga; S D Gamua; S M Ghogomu; V P K Titanji
Journal:  Parasite Immunol       Date:  2018-01-25       Impact factor: 2.280

6.  The Diversity of Lipopolysaccharide (O) and Capsular Polysaccharide (K) Antigens of Invasive Klebsiella pneumoniae in a Multi-Country Collection.

Authors:  Myeongjin Choi; Nicolas Hegerle; Joseph Nkeze; Shaichi Sen; Sanchita Jamindar; Shamima Nasrin; Sunil Sen; Jasnehta Permala-Booth; James Sinclair; Milagritos D Tapia; J Kristie Johnson; Sylla Mamadou; Joshua T Thaden; Vance G Fowler; Ana Aguilar; Enrique Terán; Dominique Decre; Florence Morel; Karen Angeliki Krogfelt; Annelie Brauner; Efthymia Protonotariou; Eirini Christaki; Yuichiro Shindo; Yi-Tsung Lin; Andrea L Kwa; Sadia Shakoor; Ashika Singh-Moodley; Olga Perovic; Jan Jacobs; Octavie Lunguya; Raphael Simon; Alan S Cross; Sharon M Tennant
Journal:  Front Microbiol       Date:  2020-06-12       Impact factor: 5.640

Review 7.  The role of vaccines in fighting antimicrobial resistance (AMR).

Authors:  Kathrin U Jansen; Annaliesa S Anderson
Journal:  Hum Vaccin Immunother       Date:  2018-07-09       Impact factor: 3.452

8.  Immunoinformatics-Aided Design and Evaluation of a Potential Multi-Epitope Vaccine against Klebsiella Pneumoniae.

Authors:  Hamza Arshad Dar; Tahreem Zaheer; Muhammad Shehroz; Nimat Ullah; Kanwal Naz; Syed Aun Muhammad; Tianyu Zhang; Amjad Ali
Journal:  Vaccines (Basel)       Date:  2019-08-12

9.  Klebsiella pneumoniae Lipopolysaccharides Serotype O2afg Induce Poor Inflammatory Immune Responses Ex Vivo.

Authors:  Matteo Bulati; Rosalia Busà; Claudia Carcione; Gioacchin Iannolo; Giuseppina Di Mento; Nicola Cuscino; Roberto Di Gesù; Antonio Palumbo Piccionello; Silvestre Buscemi; Anna Paola Carreca; Floriana Barbera; Francesco Monaco; Francesca Cardinale; Pier Giulio Conaldi; Bruno Douradinha
Journal:  Microorganisms       Date:  2021-06-17

10.  A lack of ongoing diabetes is an important factor in preserving eyes from late or suboptimally treated endogenous endophthalmitis secondary to Klebsiella pneumoniae liver abscess.

Authors:  Shwu-Jiuan Sheu; Yao-Shen Chen; Huey-Shyan Lin; Shih-Lin Chen; Pei-Jan Tsai
Journal:  Taiwan J Ophthalmol       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.